Trial Profile
A Placebo-Controlled, Two-Part Study With Single Dose and Multiple Ascending Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs CNTX 6970 (Primary)
- Indications Inflammatory pain
- Focus Pharmacokinetics
- Sponsors Centrexion Therapeutics
- 04 Sep 2019 According to a Centrexion Therapeutics media release, data will be presented at at the 13th Annual PAINWeek National Conference taking place in Las Vegas, Nevada from September 3-7, 2019.
- 19 Apr 2018 According to a Centrexion Therapeutics media release, data will be presented at the 34th Annual American Academy of Pain Medicine (AAPM) Meeting
- 26 Sep 2017 According to a Centrexion Therapeutics media release, data will be presented at the 11th Annual Pain and Migraine Therapeutics Summit 2017.